跳至主要内容
临床试验/ACTRN12624000797572
ACTRN12624000797572尚未招募Unknown

RECENTRE: Determining the Acceptability, Safety and Efficacy of The Enhancing Women's Recovery after Cancer Treatment Program.

Griffith University0 个研究点目标入组 800 人开始时间: 2024年6月27日最近更新:
适应症

试验速览

阶段
Unknown
状态
尚未招募
入组人数
800

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomised trial
主要目的
Treatment
盲法
Open (masking not used)

入排标准

年龄范围
18 Years 至 o limit(—)
性别
Female

入选标准

  • Confirmed diagnosis of breast or gynaecological cancer (all stages).
  • Have completed intensive cancer treatment more than 4 weeks ago including surgery, chemotherapy, immunotherapy and/or radiotherapy (maintenance therapy as specified by treating team permitted e.g. oral chemotherapy; targeted therapies for example trastuzumab; endocrine therapy; bisphosphonates) and up to 36 months post-intensive treatment.
  • >18 years of age.
  • Received care through any Mater facility.
  • Are residing in Queensland, Australia.
  • Cognitively capable of consent.
  • Have access to the internet with a stable connection.
  • Own, or have access to, a computer, tablet device or smartphone.
  • Willing and able to comply with all study requirements, including intervention, timing, and nature of required assessments.
  • Able to speak and read in English to ensure consent is informed and documentation of participant-reported outcome measures can be adhered to.
  • Voluntary written (electronic) informed consent.

排除标准

  • Those who do not fit the above inclusion criteria.
  • Women who are palliative, or on intensive treatment and/or unlikely to be able to complete the program, or unable to provide informed consent.
  • Any clinical contraindication that precludes safe completion of the program in the judgement of the project team

研究者

相似试验